Compare Boston Scientific Corporation (BSX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Texas Instruments Incorporated — how do they compare? Boston Scientific Corporation trades at $43.45 (market cap $66.37B), while Texas Instruments Incorporated trades at $298.82 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 4.2× Boston Scientific Corporation's market cap, and Texas Instruments Incorporated pays a 1.86% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | TXN | |
|---|---|---|
Market Cap | $66.37B | $278.08B |
Sector | Health | Technology |
52-Week High | $108.14 | $332.35 |
52-Week Low | $42.63 | $153.33 |
Enterprise Value | $75.94B | $287.03B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Texas Instruments (TXN) trades at $298.57, down 4.15% over the past day, with technical indicators showing a bearish trend. The company reported mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with revenue of $17.68 billion in 2025. Analyst sentiment is positive, with a consensus price target of $317.20 and 48% buy ratings. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
Outlook: TXN benefits from AI infrastructure growth and operational leverage, but faces risks from high valuation multiples and competitive pressures. The stock offers potential upside to the consensus target, supported by solid profitability and dividend payments, though investors should monitor debt levels and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
